N-methyl-D-aspartate receptors (NMDARs) are ion channels gated by glutamate, the major excitatory neurotransmitter in the mammalian central nervous system (CNS). They are widespread in the CNS and are involved in numerous physiological and pathological processes including synaptic plasticity, chronic pain and psychosis. Aberrant NMDAR activity also plays an important role in the neuronal loss associated with ischaemic insults and major degenerative disorders including Parkinson's and Alzheimer's disease. Agents that target and alter NMDAR function may, thus, have therapeutic benefit. Interestingly, NMDARs are endowed with multiple extracellular regulatory sites that recognize ions or small molecule ligands, some of which are likely to regulate receptor function in vivo. These allosteric sites, which differ from agonist-binding and channel-permeation sites, provide means to modulate, either positively or negatively, NMDAR activity. The present review focuses on allosteric modulation of NMDARs containing the NR2B subunit. Indeed, the NR2B subunit confers a particularly rich pharmacology with distinct recognition sites for exogenous and endogenous allosteric ligands. Moreover, NR2B-containing receptors, compared with other NMDAR subtypes, appear to contribute preferentially to pathological processes linked to overexcitation of glutamatergic pathways. The actions of extracellular H
Molecular architecture of NMDA receptors
N-methyl-D-aspartate receptors (NMDARs) are multisubunit complexes associating NR1, NR2 and, more rarely, NR3 subunits (also named GluN1, GluN2 and GluN3, respectively; Alexander et al. 2008) . NR2 and NR3 subunits exist as four and two subtypes, respectively (NR2A-D and NR3A-B), each subtype being encoded by a distinct gene. NR1 exists as seven subtypes (NR1a-g), which are generated by alternative splicing from a single gene (Dingledine et al., 1999) . Most NMDARs in the central nervous system (CNS) are comprised of NR1 and NR2 subunits forming a tetrameric complex of two NR1 and two NR2 subunits. Similarly to other glutamatereceptor ion channels (a-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) and kainate receptors), NMDARs are thought to arrange and operate as dimer of dimers (Furukawa et al., 2005) . The NR2 subunits that have differential developmental and anatomical profile are the major determinants of functional diversity by conferring on NMDARs' distinct biophysical and pharmacological properties (CullCandy and Leszkiewicz, 2004; Paoletti and Neyton, 2007) .
Structurally, NMDAR subunits, like AMPA and kainate receptor subunits, share a common design and are organized into four different modules or units (Mayer, 2006; Paoletti and Neyton, 2007;  Figure 1A ): two large domains in the extracellular region, the N-terminal domain (NTD) and the agonist-binding domain (ABD, binding glycine in NR1 and glutamate in NR2); the membrane region, comprising three transmembrane segments and a re-entrant loop that forms the ion channel and resembles an inverted K + channel; and the cytoplasmic region, comprising a C-terminal tail involved in cellular trafficking of the receptor and coupling to various intracellular signalling pathways.
The two extracellular domains, the NTD and the ABD, share homology with bacterial periplasmic proteins. The NTD, composed of the first 380 amino acids, is related to the leucine isoleucine valine binding protein (LIVBP; O'Hara et al., 1993; Paoletti et al., 2000) and plays an important role in subunit assembly (Herin and Aizenman, 2004) . In NR2A and NR2B subunits, it also forms a regulatory domain, binding allosteric inhibitors (see below). Its structure has not been determined yet, but by homology to LIVBP, it is thought to exhibit a clamshell-like structure (Masuko et al., 1999; Paoletti et al., 2000) . The ABD, which is related to the glutamine-binding protein, is also a bilobate domain. It is split in two discontinuous segments, S1 and S2, by insertion of the ion channel ( Figure 1A ). Several X-ray crystal structures of ABD of different ionotropic glutamate receptor (iGluR) subunits are now available, including those of NR1 and NR2A subunits complexed with glycine and glutamate respectively (Furukawa et al., 2005) . In all these structures, the agonist binds in the cleft of the clamshell, stabilizing a closed conformation of the two lobes. Competitive antagonists bind the same cleft but, in contrast to agonists, impede cleft closure, thus, preventing channel activation (Furukawa and Gouaux, 2003) .
The mechanism that couples agonist binding to channel gate opening is partly known. ABD dimerization plays a key role in this process. Indeed, because two neighbouring ABDs are 'attached' one to the other through back-to-back apposition of their lobe 1, ABD closure induced by agonist binding can be transduced into tension onto the linkers connecting the ABDs to the channel. This in turn leads to channel opening (Mayer, 2006; see Figure 4B later) . Breaking of the ABD dimer interface provides a means to relax this tension, and hence, close the channel. This process occurs during AMPA and kainate receptor desensitization (Sun et al., 2002; Mayer, 2006) and during allosteric inhibition of NMDARs by protons and NTD ligands (Gielen et al., 2008 ; see also, below and Figure 2B ).
The NR2B subunit: expression and subcellular localization
While the NR1 subunit is expressed in virtually all neurons and at all developmental stages in the brain, NR2 subunit genes display different regional and developmental expression patterns. Thus, in the embryonic brain, NR2B and NR2D subunits predominate, while NR2A and NR2C are absent; in contrast, in the adult brain, NR2A predominates, being ubiquitously expressed, while NR2B expression is restricted to forebrain areas, and NR2C is highly enriched in the cerebellum (Watanabe et al., 1992; Akazawa et al., 1994; Monyer et al., 1994, Figure 1B) . Closer inspection of NR2B subunit gene expression in the rodent brain indicates that at E17, high levels of NR2B are present in the cortex (especially layer I), thalamus and spinal cord. In this latter region, NR2D is also strongly expressed. Around birth, NR2B expression is wide- spread with strong expression levels in the cortex, hippocampus, septum, striatum and thalamic nuclei. NR2B is also present in the developing cerebellum, though at lower levels. NR2B expression peaks around P7-P10, at a stage where NR2A expression rises sharply while NR2D drops. The most striking change in the pattern of NR2B gene expression takes place between the first and second week post-natal and results in its almost complete disappearance from the cerebellum (while NR2C, and to a lesser extent, NR2A increase) together with a confinement to forebrain structures. In the cerebellum, this switch in NR2 subunit expression from NR2B to NR2A and NR2C has been shown to occur in the same cell population, the granule cells (Farrant et al., 1994) . In the adult brain, expression of NR2B is the highest in the cortex (most particularly layer II/III), hippocampus, amygdala, ventral nuclei of the thalamus and olfactory bulb (Watanabe et al., 1993) . Interestingly, in the adult spinal chord, NR2B expression is restricted to lamina 2 of the dorsal horn, a region that receives primary sensory afferents from nociceptors and thermoreceptors (Watanabe et al., 1994) . The restricted localization of NR2B-containing receptors in this region could explain, in part, why NR2B-selective antagonists have analgesic effects (Chizh et al., 2001 and see below) . At the subcellular level, NMDARs, including those containing NR2B, have been detected on synaptic, perisynaptic and extrasynaptic sites (Köhr, 2006) . In most neurons, however, the density of NMDARs is higher in dendritic spines, within the postsynaptic density, than in the dendritic shaft and somatic membrane. At immature glutamatergic synapses, it is well established that NR2B-containing receptors predominate and mediate direct synaptic transmission. With maturation, the increase in NR2A expression usually results in faster decay kinetics and decreased sensitivity of synaptic currents to NR2B-selective antagonists. Moreover, several studies have shown that extrasynaptic NMDARs are enriched in NR2B subunits compared with synaptic receptors. These extrasynaptic NMDARs may be activated by spillover of glutamate released from multiple neighbouring synaptic sites (Scimemi et al., 2004) . However, in the adult brain, the segregation of NR2B and NR2A to extrasynaptic and synaptic sites is not absolute, and there are clear examples of adult synapses where NR2B subunits predominate (see for instance, Lopez de Armentia and Sah, 2003) . The fact that at many adult synapses, NR2B subunits might incorporate preferentially into triheteromeric NR1/NR2A/NR2B receptors (Luo et al., 1997) , a receptor subtype shown only recently to have a low sensitivity to NR2B-selective antagonists (Hatton and Paoletti, 2005) , is likely to explain why certain groups have proposed that NR2B is excluded from synaptic sites. Finally, there is accumulating evidence that NMDARs are also present at presynaptic sites where they can influence transmitter release. In particular, NR2B-containing autoreceptors have been described on primary sensory afferents of the spinal chord (Ma and Hargreaves, 2000) , and at synapses on entorhinal cortical neurons (Woodhall et al., 2001) . Similarly to postsynaptic NMDARs, presynaptic NMDARs may also participate in certain forms of synaptic plasticity (Pinheiro and Mulle, 2008) .
Allosteric inhibition by protons
Extracellular protons (H + ) are potent inhibitors of NMDARs. They inhibit NMDARs in a non-competitive and voltageindependent manner, indicating that they are not acting as channel blockers (Tang et al., 1990; Traynelis and Cull-Candy, 1990; Vyklicky et al., 1990) . As a consequence of NMDAR inhibition by protons, mild extracellular acidosis accompanying ischaemia and seizures may minimize glutamate-induced neuronal damage (Giffard et al., 1990 ; and see Dingledine et al., 1999) . Sensitivity of NMDARs to extracellular protons depends on subunit composition, with influence of both NR1 and NR2 subunits. Receptors containing the NR2C subunit are the least sensitive with an IC50 of~pH 6.5 (Traynelis et al., 1995; Low et al., 2003) . Receptors made of NR1a and NR2A have an intermediate pH sensitivity with an IC50 of~pH 6.9 (when extracellular ambient zinc is chelated; Low et al., 2000; . NR1a/NR2B and NR1a/NR2D receptors display the highest pH sensitivity with an IC50 of~pH 7.4 (Traynelis et al., 1995) . This implies that, under normal conditions, about half of NR1a/NR2B receptors are under tonic proton inhibition; it also suggests that small changes in extracellular pH can significantly alter the amount of current flowing through these receptors. Accordingly, endogenous alkaline transients fol- (Makani and Chesler, 2007) . Proton sensitivity is also modulated by alternative splicing of the NR1 subunit. Inclusion of NR1 exon-5 (NR1b subunit) reduces proton sensitivity, an effect that has been attributed to the shielding of the proton sensor by positively charged residues present at the C-terminus end of exon-5 (Traynelis et al., 1995; . It is interesting to note that exon-5-containing NR1b/NR2A and NR1b/NR2B receptors have equal proton sensitivity, with IC50s close to pH 6.7 (Traynelis et al., 1995) . Although many residues, both on NR1 and NR2 subunits, have been shown to control proton inhibition (Traynelis et al., 1998; Masuko et al., 1999; Low et al., 2000; , the precise location of the proton 'sensor' (assuming that it forms a discrete site) remains unknown. Extensive mutagenesis has revealed that residues that influence proton sensitivity most strongly cluster in two neighbouring regions (Low et al., 2003 ; but see Gielen et al., 2008) : (i) the lurcher region, composed of the 'SYTANLAAF' motif and located in the extracellular end of the second transmembrane segment (M2); and (ii) the linkers connecting the ABD S2 segment to the transmembrane segments (S2-M2 and S2-M3 linkers). These regions are closely associated with the activation gate of NMDARs (Chang and Kuo, 2008) . The proton sensor is therefore likely to be tightly coupled to the movement of the NMDAR channel gate. Single-channel studies at NR1/NR2B receptors reveal that protons prolong one of the shut-time components, while it has almost no effect on channel open time (Banke et al., 2005) . These data strongly suggest that protons preferentially act by stabilizing a closed state rather than destabilizing the open state.
Modification of proton sensitivity appears to be a common downstream mechanism of a number of NMDARs' allosteric modulators. Thus, ifenprodil, exon-5 insert and polyamines at NR2B-containing receptors, and extracellular zinc at NR2A-containing receptors, all alter NMDAR function by shifting the pKa of the proton sensor (Traynelis et al., 1995; Mott et al., 1998; Choi and Lipton, 1999; Low et al., 2000 and see below) . These data reinforce the idea that the proton sensor and the channel gate are structurally and functionally integrated.
Modulators binding the interlobe cleft of the NR2B NTD
One important recent development in NMDAR function and pharmacology has been the discovery that the NTDs of NR2A and NR2B subunits form discrete modulatory domains binding non-competitive antagonists with strong subunit selectivity (Herin and Aizenman, 2004) . So far, only the zinc ion has been identified as being a ligand of the NR2A-NTD (Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000; Paoletti et al., 2000) . Zinc binds the large interlobe crevice of the NTD and, by interacting with residues from both lobes 1 and 2, promotes its closure by a hinge bending mechanism, as seen in other clamshell-like domains (Paoletti et al., 2000) . Binding of zinc to the NR2A-NTD is responsible for the exquisite (nM) sensitivity of NR2A-containing receptors to extracellular zinc (IC 50~15 nM for NR1/NR2A receptors; Chen et al., 1997; Paoletti et al., 1997; Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000; Paoletti et al., 2000; Hatton and Paoletti, 2005) . The NTD of NR2B (but not that of NR2C and NR2D) also binds zinc, but with a much lower affinity. This modulatory site accounts for the low micromolar voltage-independent zinc inhibition of NR1/NR2B receptors (IC50~1 mM; Traynelis et al., 1998; Rachline et al., 2005) . Thus, when applied at nanomolar concentrations (up to~300 nM), zinc selectively inhibits receptors containing the NR2A subunit, a property than can be used to discriminate between NMDAR subtypes in physiological experiments (see Neyton and Paoletti, 2006) . Moreover, because zinc is concentrated and released at many glutamatergic synapses in the CNS (Vogt et al., 2000; Paoletti et al., 2009) , zinc is a potential candidate for an endogenous ligand of the NTDs of both NR2A and NR2B subunits. However, whether extracellular zinc acts as an in vivo regulator of NMDAR activity remains unknown.
Besides the zinc ion, the NR2B-NTD also binds ifenprodil [compound (1), Figure 2 ] and derivatives, a large family of synthetic organic compounds (Perin-Dureau et al., 2002) . Although first described as a cerebral vasodilator (Carron et al., 1971) , ifenprodil was later reported to have a neuroprotective action through non-competitive antagonism of NMDARs (Carter et al., 1988) . In 1993, Williams made the remarkable observation that ifenprodil displays strong (>100-fold) preference among the various NR1/NR2 receptor subtypes, by selectively inhibiting receptors containing the NR2B subunit (IC 50~150 nM; Williams, 1993) . Ever since this discovery, ifenprodil and derivatives have proven extremely useful as pharmacological tools to study the structure and function of NMDARs. They have also triggered intense pharmaceutical interest because of their therapeutic potential for a range of neurological and psychiatric disorders (see below).
Studies on chimeric NR2A/NR2B subunits and on isolated NTDs produced in bacteria mapped ifenprodil-binding site to NR2B-NTD (Gallagher et al., 1996; Perin-Dureau et al., 2002; Wong et al., 2005; Ng et al., 2007; 2008; Han et al., 2008 ). An extensive mutagenesis scan, combined with molecular modelling, further supported the hypothesis of ifenprodil binding in the large interlobe cleft of the NR2B-NTD (Perin-Dureau et al., 2002) . Functional studies also revealed that zinc and ifenprodil act in a mutually exclusive manner at NR2B-NTD, competing for putative binding sites that partially overlap (Rachline et al., 2005) . No model of zinc binding has been proposed yet, but the zinc ion is likely to interact with histidine 127, glutamate 47 and aspartate 265, all located in the NR2B-NTD interlobe cleft (Rachline et al., 2005) , and bearing side chains commonly found in zinc-binding sites (Alberts et al., 1998) . The first experimentally validated 3D model of ifenprodil docked in its binding pocket has recently been described (Mony et al., 2009 ). In this model, ifenprodil occupies the NTD cleft, almost perpendicular to the plane of the hinge. The NTD cleft is in a closed conformation and ifenprodil directly interacts with residues both from lobes 1 and 2, lending support to a model in which ifenprodil binding promotes closure of the NR2B-NTD. The ifenprodil molecule adopts a conformation in which its benzyl group contacts hydrophobic residues at or near the NTD hinge, while its phenol moiety makes hydrogen bonds with polar residues at the entrance of the cleft. The central piperidine moiety makes both Van der Waals interactions with F176 and ionic interactions with D101. The fact that this latter residue may also be directly involved in zinc coordination would explain why ifenprodil and zinc cannot occupy the NR2B-NTD cleft simultaneously (Rachline et al., 2005) .
Opposing an ifenprodil-binding site entirely formed by NTD-NR2B residues, some data in the literature suggest that determinants of ifenprodil binding may reside on the NR1 subunit. Thus, Masuko et al. (1999) found mutations in NR1-NTD lobe 1 that affect ifenprodil inhibition, while Han et al. (2008) showed that isolated NR1-NTDs, similarly to isolated NR2B-NTDs (but not NR2A-NTDs), bind radiolabelled ifenprodil. The NR1 residues highlighted by Masuko et al. (1999) are located at positions homologous to residues participating in hydrophobic dimerization interfaces in other receptors containing LIVBP-like domains. Rather than directly binding ifenprodil, these residues may therefore be involved in the transduction of the ifenprodil-induced conformational changes of NR2B-NTD (see Perin-Dureau et al., 2002) . Moreover, it is possible that such hydrophobic residues fortuitously bind ifenprodil when NR1-NTD is isolated in a polar solvent. In fully assembled NR1/NR2 receptors, this potential binding site is likely to be masked following NR1 and NR2 NTD dimerization.
Ifenprodil is the prototypical member of a large, and growing, family of NR2B-selective antagonists that can be usefully grouped as 'prodils'. Among them are synthesized analogues offering improved potency (at NR1/NR2B receptors) and selectivity versus additional 'off' target activities such as adrenergic and sigma receptors (Kew and Kemp, 1998; Chenard and Menniti, 1999; Nikam and Meltzer, 2002; Borza and Domany, 2006) . The best characterized compounds and, consequently, those most commonly used as pharmacological tools are traxoprodil or CP-101,606 [Chenard et al., 1995, (5) ], besonprodil [CI-1041, (6), Chizh et al., 2001] and Ro 25-6981 [Fischer et al., 1997, (7) ], all of which are~10-fold more potent than ifenprodil; the recently disclosed RGH-896 or radiprodil (8) can also be considered to form part of this chemical group ( Figure 3A ). These 'second generation' compounds, which share the same structural features as ifenprodil, are likely to bind in a similar mode to the NR2B-NTD (see Malherbe et al., 2003 for Ro 25-6981) . Large-scale screening approaches and medicinal chemistry efforts have also led to the identification of further novel NR2B-selective antagonists such as MK-0657 (9) ( Figure 3B ) and EVT-101 (structure not disclosed). These agents, like radiprodil, have good potency at NR2B-containing receptors and enhanced oral bioavailability compared with earlier agents, and have been progressed into the clinic by Merck, Evotec and Gedeon Richter/ Forest Laboratories respectively (see Table 1 ). Recently, a more diverse array of structures have been described as NR2B antagonists including ( Figure 3B ) indole-and benzimidazole-2-carboxamides 2007, (10) ], 2-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines [Büttelmann et al., 2003, (11) ], benzamidines [Claiborne et al., 2003, (12) ], N-(phenylalkyl)cinnamides [Tamiz et al., 1999, (13) ], N1-(benzyl)cinnamamidines Kiss et al., 2005, (14) ], 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-ylamines [Alanine et al., 2003, (15) ], Taisho's HON0001 [Suetake-Koga et al., 2006, (16) ] and di-imidazoles (17). Many of these structurally distinct compounds are highly potent, with low nanomolar affinities at NR1/NR2B. However, whether these latest generation NR2B-selective antagonists have a similar binding mode to ifenprodil remains to be determined. The recently proposed 3D model of ifenprodilbinding site into NR2B-NTD (Mony et al., 2009 ) provides a useful approach to tackle this question. The transduction cascade that couples binding of the modulatory NTD ligand to receptor inhibition (i.e. channel gate closure) has been recently dissected in the case of the high-affinity zinc inhibition of NR1/NR2A receptors (Gielen et al., 2008 , and see Figure 4B ). First, zinc binds the interlobe cleft of the NR2A-NTD and promotes its closure. This closure then exerts tension on the linkers connecting the NTDs to the ABDs, an effect that triggers disruption of the ABD dimer interface; this in turn relieves the strain on the transmembrane segments, and together with proton binding, allows closure of the channel gate. This mechanism shows common features with that underlying fast desensitization of AMPA and kainate receptors, where conformational rearrangements at the ABD dimer interface also occur (Sun et al., 2002) . The inhibition of NR2B-containing receptors following zinc or ifenprodil binding to the NR2B-NTD may proceed through a similar mechanism to that described for zinc on NR1/NR2A receptors. The fact that ifenprodil inhibition of NR1/NR2B receptors reflects an enhancement of tonic proton inhibition Mott et al., 1998) , similarly to zinc inhibition of NR1/NR2A receptors (Choi and Lipton, 1999; Low et al., 2000) , argues in this direction. However, zinc inhibition of NR1/NR2B receptors appears not to depend on pH (Traynelis et al., 1998; Low et al., 2000) , suggesting that zinc binding to NR2B-NTD may inhibit NR1/NR2B receptors through a different mechanism.
Polyamines: NR2B-selective positive allosteric modulators
Polyamines are polybasic aliphatic amines that are positively charged at physiological pH. The endogenous polyamines, spermine [(3), Figure 2 ], spermidine and putrescine, are synthesized from ornithine, a by-product of the urea cycle. Polyamines are widely distributed throughout the body and are found at high intracellular levels, where they interact with nucleic acids and proteins, including plasma membrane ion channels. In the CNS, there is also evidence that, under certain conditions, polyamines may be present in the extracellular medium, where they would act as modulators of neuronal excitability. First, polyamines are released in a Ca 2+ -dependent manner following neuronal stimulation; second, high-affinity uptake systems for polyamines exist; and third, extracellular polyamines interact with various ion channels and receptors, including calcium channels and NMDARs (Rock and Macdonald, 1995) .
Extracellular polyamines have multiple effects on NMDAR responses (Rock and Macdonald, 1995) . Early patch-clamp Allosteric modulators of NR2B-containing NMDA receptors L Mony et al studies on native NMDARs from cultured hippocampal neurons showed highly variable effects of polyamines, ranging from a strong enhancement to a marked inhibition depending upon the particular cell examined (Benveniste and Mayer, 1993) . It is now well established that this variability can be accounted for different levels of expression of NMDAR subpopulations in individual cell, together with differential effects of polyamines depending on receptor subunit composition.
Spermine (and spermidine) produces three different effects on NMDARs: a voltage-dependent block, a glycine-dependent potentiation and a voltage-independent and glycineindependent potentiation. The voltage-dependent block is due to spermine entering the pore and occluding ion fluxes, much like the block produced by extracellular Mg 2+ (Rock and MacDonald, 1992) . It is highly voltage-dependent with IC50 values of 350 mM at -60 mV and 27 mM at 0 mV (NMDAR responses from cultures hippocampal neurons; Benveniste and Mayer, 1993) . In contrast to Mg 2+ , at very hyperpolarized potentials, polyamines may escape their blocking site by permeating the NMDAR channel (Araneda et al., 1999) . The polyamine block has the same subunit dependence as the 
Mg
2+ block, being less pronounced for NR2C-containing and NR2D-containing receptors than for NR2A-containing or NR2B-containing receptors (these latter two having the same degree of blockade; Williams et al., 1994) . Finally, mutations in the pore at the critical asparagines residues (Q/R/N site) that suppress Mg 2+ block also suppress spermine block, indicating a shared binding site deep in the pore (Kashiwagi et al., 1997; Traynelis et al., 1998) .
Polyamines can enhance NMDAR responses by increasing the apparent sensitivity for glycine (glycine-dependent potentiation). This is reflected by the fact that at low glycine concentrations, polyamines stimulate NMDAR responses to a greater extent than at saturating glycine concentrations (McGurk et al., 1990) . In the presence of 1 mM spermine, the apparent affinity for glycine increases by~3-fold, an effect largely due to a decrease in the rate of glycine dissociation from its binding site on NR1 (Benveniste and Mayer, 1993) . Glycine-dependent potentiation occurs both at NR2A-containing and NR2B-containing receptors but not at NR2C-containing and NR2D-containing receptors (Zhang et al., 1994; Williams et al., 1995) . Moreover, in contrast to the voltage-independent and glycine-independent potentiation (see below), the glycine-dependent stimulation is not influenced by the type of NR1 subunit splice variants. The polyamine-binding site mediating the glycine-dependent potentiation is unknown, but may reside on the NR1 subunit that harbours the glycine-binding site. In physiological conditions, it is likely that this site is partially occupied by endogenous Ca 2+ and/or Mg 2+ because both cations also increase glycine sensitivity when present at The bars above the current traces indicate the duration of agonist, spermine and histamine applications. Note that application of 100 mM histamine has no effect on NR1a/NR2B receptors while spermine does (same cell). Note also that spermine potentiation is absent on NR1a/NR2A receptors. (B) Two hypothetical mechanisms of how a polyamine could potentiate NR2B-containing receptors. These models are based on the mechanism proposed for allosteric inhibition of NR1/NR2A receptors (Gielen et al., 2008) . While the full receptor is a tetramer, only a NR1/NR2B heterodimer is shown. It is hypothesized that NTDs dimerize, and that closures of the NTDs can inactivate the receptors (i.e. induce channel gate closure) by pulling apart the ABD dimer interface ('desensitized' state). Mechanism (1): the polyamine molecule binds between the NR1 and NR2 NTD lobes II, making NTD closure, and ABD dimer interface disruption, more difficult. Mechanism (2): the polyamine molecule directly binds and stabilizes the ABD dimer interface. Entry into the 'desensitized' state is thus disfavoured. This mechanism resembles that described for cyclothiazide-induced suppression of desensitization at AMPA receptors (Sun et al., 2002; Mayer, 2006) . In both models, proton binding, which stabilizes a closed state of the channel (Banke et al., 2005) , is proposed to be closely associated with ABD dimer interface breaking (Gielen et al., 2008) . ABD, agonist-binding domain; AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazole-propionate; Glu, glutamate; Gly, glycine; NTD, N-terminal domain. (Wang and MacDonald, 1995; see Paoletti et al., 1995) . The third effect of polyamines on NMDARs is a potentiation, which is both voltage-independent and glycineindependent because it can be observed both at negative and positive membrane potentials and with saturating glycine concentrations (McGurk et al., 1990; Lerma, 1992; Benveniste and Mayer, 1993; Lu et al., 1998;  Figure 4A ). With spermine, the EC50 for this effect is~150 mM and results in a maximal potentiation around threefold (at pH 7.3; Benveniste and Mayer, 1993) . Remarkably, the voltage-independent and glycine-independent polyamine potentiation is observed exclusively at receptors that incorporate the NR2B subunit (Williams, 1994a; Williams et al., 1994; Zhang et al., 1994; Traynelis et al., 1995;  Figure 4A ). Studies on recombinant NR1/NR2B receptors have revealed that the NR2B-specific polyamine potentiation arises from the relief of tonic proton inhibition. Thus, at physiological pH, polyamines enhance NR1/NR2B responses by shifting the pKa value of the proton sensor towards more acidic values (Traynelis et al., 1995) . Accordingly, at NR1/NR2B receptors, there is a strong correlation between the proton sensitivity and the degree of polyamine potentiation (Traynelis et al., 1995; .
Allosteric modulators of NR2B-containing NMDA receptors L Mony et al
Many mutations that affect the NR2B-specific polyamine potentiation have been described. These mutations, usually of acidic residues, are found both on NR1 and NR2 subunits and are scattered throughout the extracellular region. Most of these mutations (if not all) also modify proton sensitivity (Traynelis et al., 1995; Williams et al., 1995; Kashiwagi et al., 1996; Masuko et al., 1999) . In consequence, it is still unclear whether these mutations alter polyamine potentiation directly, by disrupting the polyamine-binding pocket, or indirectly, by changing the proton sensitivity. Based on our recent finding that proton inhibition of NMDARs involves disruption of the ABD dimer interface (Gielen et al., 2008) , we propose two mechanisms by which polyamines could relieve tonic proton inhibition and thus enhance activity of NR2B-containing receptors ( Figure 4B) . In a first model, the polyamine molecule would act similarly than cyclothiazide on AMPA receptors (Sun et al., 2002) : it would bind at the ABD dimer interface and stabilize the dimer assembly. By doing so, it would decrease pH sensitivity by rendering ABD dimer disruption more difficult (an effect that would also account for the spermine-induced acceleration of NMDAR current deactivation; Rumbaugh et al. 2000) . In a second model, the polyamine would bind at the level of the NTDs, between the two 'bottom' lobes of a NTD pair. By 'gluing' together these lobes, the polyamine would render NTD closure less favourable, an effect that in turn would tend to stabilize the ABD dimer interface (and thus decrease proton sensitivity; Gielen et al., 2008) . In agreement with this mechanistic scheme, 3D homology modelling of a NR1/NR2B NTD pair indicates that many of the acidic residues of NR1 and NR2B known to control glycine-independent spermine potentiation locate on the side of the NTD 'bottom' lobes, with residues of NR2B facing those of NR1. This suggests a polyamine-binding site at the boundary between the two NTD 'bottom' lobes (Huggins and Grant, 2005) . The absence of some of these acidic residues in the NTDs of the other NR2 subunits could explain why the glycine-independent potentiation by polyamines requires the NR2B subunit. A model in which the polyamine molecule binds the NR1/NR2B NTD interface and holds the NTDs open, while ifenprodil binds in the NR2B-NTD cleft and promotes its closure, is fully consistent with the proposal of Kew and Kemp (1998) that spermine and ifenprodil bind distinct sites that interact in a negative allosteric manner (with binding of spermine promoting ifenprodil dissociation and vice versa; see also Han et al., 2008) .
The neurotransmitter histamine has been proposed to act as an endogenous activator of the NR2B-specific polyamine modulatory site (Williams, 1994b) . However, results from our lab ( Figure 4A ) and that of Steven Traynelis (pers. comm.) show a lack of effect of histamine on responses mediated by NR1a/NR2B receptors. The reason for this discrepancy remains unclear. Finally, Mg 2+ , but not Ca 2+ , mimics the glycine-independent potentiating effect of polyamine at NR2B-containing receptors (Paoletti et al., 1995; Kew and Kemp, 1998) . With an Mg 2+ EC50 of~2.0 mM close to physiological concentration of extracellular Mg 2+ , the NR2B-specific polyamine potentiating site is likely to be partially occupied by the magnesium ion under physiological conditions.
Negative and positive allosteric modulation by neurosteroids
Most steroids act like hormones being synthesized by glandular tissues and released into the general circulation system. Steroids diffuse through membranes and bind intracellular receptors, which in turn interact with transcription factors to enhance or suppress gene expression. Because of the necessity for activation of the transcriptional and translational machineries, the physiological responses induced by steroids usually take hours to days. Steroids synthesized in the periphery can cross the blood-brain barrier and produce changes in mood and behaviour (Belelli and Lambert, 2005) . The brain is also capable of synthesizing steroids de novo (Robel and Baulieu, 1994) . Neurosteroids are normally present at nanomolar concentrations in the CNS, but their levels can increase significantly following stress, for instance. In contrast to the classical genomic effects of steroids, endogenous neurosteroids act locally and produce acute effects on neuronal excitability, with time delays ranging from seconds to minutes, suggesting direct modulatory effects on membrane proteins. It is now well established that gamma-amino butyric acid-A (GABA-A) receptors, which mediate most of the inhibitory transmission in the CNS, are major targets of neurosteroids (Belelli and Lambert, 2005) . Neurosteroids also regulate NMDARs. At these receptors, neurosteroids exert either positive or negative effects depending both on the neurosteroid chemistry and the receptor subunit composition.
Pregnenolone sulfate [PS (4), Figure 2] , one of the most abundant neurosteroids and a negative modulator of GABA-A receptors, was initially shown to potentiate native NMDARs but not AMPA and kainate receptors (Wu et al., 1991; Bowlby, 1993) . PS is a derivative of pregnenolone, which is formed by cleavage of cholesterol side chain in glial cells. Potentiation of NMDAR responses by PS is voltage independent, does not Allosteric modulators of NR2B-containing NMDA receptors L Mony et al affect single-channel conductance and occurs only at relatively high concentrations of PS (>1 mM). Interestingly, when applied in the extracellular medium, PS increases NMDAR activity recorded not only from excised outside-out patches but also from cell-attached patches, indicating that the lipophilic PS may penetrate the cell membrane and reach NMDAR channels by diffusion (Bowlby, 1993) . PS differentially modulates activity of recombinant NR1/NR2 NMDARs. It potentiates NR1/NR2A and NR1/NR2B receptors (with EC50 in the 10-30 mM range) while it inhibits, in a non-competitive manner, NR1/NR2C and NR1/NR2D receptors (with IC50 in the 100-200 mM range; Malayev et al., 2002; Horak et al., 2006) . The mechanism of action of PS at NR1/NR2B receptors has been studied using fast perfusion techniques on transfected human embryonic kidney (HEK)-293 cells. Strikingly, the degree of PS potentiation is an order-of-magnitude larger when PS is applied just before than during NMDAR activation, indicating that the PS affinity is strongly decreased after glutamate binding (Horak et al., 2004) .
PS enhances NMDAR responses by acting at a site that likely differs from the site(s) responsible for spermine potentation (Park-Chung et al., 1997) . By constructing chimeric NR2B/ NR2D (Jang et al., 2004) or NR2A/NR2C (Horak et al., 2006) subunits, the PS potentiating site has been recently mapped to a region encompassing the M2-M3 extracellular loop and the M3 transmembrane segment. In the NR2 M2-M3 loop, helices J and K appear to be important for PS sensitivity (Jang et al., 2004) . Because helix J is a key constituent of the dimer interface between neighbouring NR1-NR2 ABDs, Jang et al. (2004) have proposed that PS binds and stabilizes this interface very much like the positive allosteric modulator cyclothiazide on AMPA receptors. There are, however, experimental data that are difficult to reconcile with a PS-binding site at the ABD dimer interface. First, PS potentiation appears to be functionally independent from proton inhibition (Jang et al., 2004) , whereas stability of the ABD dimer is closely correlated to proton sensitivity (Gielen et al., 2008) . Second, the transmembrane segment M3 appears critical for the potentiating effect of PS, suggesting that this region may contain residues directly binding PS (Jang et al., 2004) . Thus, the potentiating effect of PS on NMDARs may be mediated by a site in the membrane region rather than at an extracellular location. The lipophilic nature of PS and the very slow kinetics of its action at NR1/N2B receptors (Horak et al., 2004) are compatible with this hypothesis. It is interesting to note that at GABA-A receptors, transmembrane sites are responsible for the regulatory effects of neurosteroids on these receptors (Hosie et al., 2006) .
The PS analogue 3a-hydroxy-5b-pregnan-20-one sulphate [3a5bS (2), Figure 2 ] is another endogenous neurosteroid that modulates NMDAR activity. 3a5bS inhibits native and recombinant NMDARs, with little selectivity among the different NR1/NR2 receptor subtypes. It acts in a voltage-independent and non-competitive manner, strongly arguing for a binding site outside the pore and the agonist-binding pockets (Parkchung et al., 1994; Park-Chung et al., 1997; Malayev et al., 2002; Petrovic et al., 2005) . Thus, despite strong chemical similarity, PS and 3a5bS produce opposite effects at NR1/ NR2A and NR1/NR2B receptors, the former acting as a positive allosteric modulator and the latter as a negative allosteric modulator. Structure-activity studies on the steroid molecules have led to the identification of important structural features that determine the action of neurosteroids at NMDARs. The presence of a negative charge (bulky or not) at the C3 position seems mandatory for both the potentiating and inhibitory effects of neurosteroids on NMDARs (Park-Chung et al., 1997; Weaver et al., 2000) . Moreover, the geometry of the neurosteroid strongly influences the sign of the modulatory effect. Neurosteroids having a bent geometry (3a5bS and 3b5bS) inhibit native NMDAR responses (mostly from NR2A-containing and/or NR2B-containing receptors), whereas those having a more planar configuration (PS and 3b5aS) potentiate such responses (Weaver et al., 2000) . Thus, whether a neurosteroid enhances or decreases NMDAR activity critically depends on the geometry of its A-B ring junction, a parameter that is determined by the stereochemistry of the C5 position.
NR2B-containing receptor function and the therapeutic potential of subtype-selective NMDAR modulation
There is currently great interest in determining whether different NMDAR subtypes make specific contributions to physiological and pathological neuronal processes. Dissection of the roles of NMDAR subtypes can be performed using genetic (genetically modified mice, RNAi-mediated gene interference) or pharmacological tools. All of these approaches have recognized limitations (e.g. see Neyton and Paoletti, 2006 for the pharmacological approach) and, hence, despite intense investigation, there are many controversial issues in the field. Several parameters may strongly influence the role that a NMDAR subtype may play: (i) its particular receptor subunit composition, which determines the level of receptor activity and kinetic behaviour; (ii) its subcellular location (synaptic or extrasynaptic); (iii) its coupling to downstream signalling cascades (these latter two parameters being likely dependent on the subunit composition); and (iv) potential changes in its expression or activity linked to disease. Based on our current understanding of the roles of the different NMDAR subtypes in normal physiology and in pathophysiological conditions, it appears that subtypeselective modulation of receptor function offers emerging therapeutic potential for the treatment of a range of CNS disorders. Thus, NR2B-selective antagonists may offer utility for the treatment of disorders including chronic pain, Parkinson's disease, Huntington's disease, Alzheimer's disease, cerebral ischaemia and major depression.
Notably, while non-selective NMDAR antagonists commonly exhibit a range of side effects including behavioural, cardiovascular and potentially cytotoxic activities, which have limited their therapeutic development, NR2B-selective antagonists are relatively well tolerated (Kemp et al., 1999; Chazot, 2004; Gogas, 2006) . In addition to the inherent sparing of non-NR2B-containing receptor function as a consequence of subtype selectivity, including a relative lack of effect in brain regions with little or no NR2B expression, such as the cerebellum, ifenprodil and related compounds also display an activity-dependent mode of action; they bind with a higher affinity to the activated and desensitized states of the (Kew et al., 1996; Fischer et al., 1997; Gill et al., 2002) . Thus, these compounds preferentially block NMDARs continuously or repetitively activated, as may be the case in pathological conditions, while leaving those that are physiologically activated relatively unaffected. In addition, as ifenprodil inhibition of the NR2B-containing receptors is mediated through an enhancement of proton inhibition Mott et al., 1998) , antagonist efficacy would be further increased under pathological conditions where pH levels also fall, such as in ischaemia (Silver et al., 1992) . Thus, both the mechanism of action and subunit selectivity contribute to the relative lack of adverse events/good tolerability profile associated with this compound class (Kemp et al., 1999; Gogas, 2006) .
Although most studies point towards an improved therapeutic index with the NR2B-subtype-selective approach, recent studies have raised concerns regarding the role of NR2B in mediating phencyclidine (PCP)-like behavioural effects and the potential for abuse liability as previously associated with pan-NMDAR antagonists, such as ketamine. Preclinical studies with Ro 25-6981 (Chaperon et al., 2003) and CP-101,606 (Nicholson et al., 2007) suggest a role of NR2B in producing the subjective and reinforcing effects associated with PCP in rodents and primates. Although noted to be generally well tolerated in the clinic, some indications of such activity have emerged in recent clinical studies with CP-101,606 (Table 1) . Further work is, therefore, required to explore these aspects in more detail, especially for the latest NR2B-selective antagonists progressed into the clinic, to determine if an acceptable balance between efficacy and side effects exists to support their further development for the treatment of the range of disorders outlined below.
Therapeutic potential of NR2B-selective antagonists
Pain Clinically, broad-spectrum NMDAR antagonists (e.g. ketamine, dextromethorphan) are reportedly used off label for the treatment of neuropathic pain (Chizh et al., 2001; ; they have good efficacy, but suffer from a generally unacceptable side-effect profile due to a very narrow therapeutic index. The rationale for developing subtype-selective NMDAR antagonists therefore stems from a desire to maintain NMDAR-mediated efficacy while moving away from the side effects resulting from indiscriminate broad NMDAR blockade. Initial focus on NR2B derived from the more localized expression of NR2B in the dorsal horn of the spinal cord as well as in higher brain centres thought to be important for the relay and conscious perception of pain, for example, the thalamus and anterior cingulate cortex (Figure 1 ). The availability of the 'prodil' class of NR2B-selective antagonists (Figure 3 ) has led to rapid progress in validating NR2B-containing NMDARs as a target for the treatment of pain, with many studies reporting efficacy of such agents in models of acute (Taniguchi et al., 1997; Boyce et al., 1999) and chronic inflammatory (Wilson et al., 2006) , neuropathic (Boyce et al., 1999) and even visceral pain (Boyce et al., 2002) at doses that are devoid of overt behavioural side effects. More recent research has also defined a key involvement of NR2B-containing receptors in mechanisms, such as 'wind up' and 'central sensitization', that operate spinally and supraspinally, and which may explain the apparent broad-spectrum activity of NR2B antagonists across the various disease models. These pharmacological studies have been complemented by additional insight into the role of NR2B-containing receptors in pain gained from studies with transgenic mice overexpressing NR2B in the forebrain which display a selective enhancement of persistent pain and allodynia (Wei et al., 2001) . Similarly, intrathecal administration of siRNAs against the NR2B subunit reduces the pain responses induced by peripheral inflammation (Tan et al., 2005) .
The potential of NR2B antagonists for the treatment of pain has now gained clinical precedence based on the observed efficacy of CP-101,606 in a placebo-controlled crossover phase 2a study in spinal cord injury and monoradiculopathy patients, where a significant reduction in pain score was seen following i.v. dosing of CP-101,606 (Sang et al., 2003) . CP-101,606 was reasonably well tolerated in this study but did yield some CNS side effects (Table 1) . Despite these encouraging data, subsequent progress in this field has been hampered by the lack of compounds with good orally bioavailability, appropriate selectivity versus human ether-a-gogo related gene (hERG), and concerns regarding CNS side effects and abuse potential as discussed above. Despite these challenges, Gedeon Richter and Forest Laboratories, Merck and Evotec have now identified orally bioavailable agents that have progressed into clinical development (Table 1) . To date, only limited information concerning the safety profile of these agents in phase 1 trials is available, and this provides some basis for optimism (Table 1 ). However, it will only be with efficacy data from appropriate phase 2 studies that these initial findings can be put into context of therapeutic index and the prospects for further development fully evaluated.
Parkinson's disease
The degeneration of nigral dopaminergic neurons and the depletion of dopamine from the nigro-striatal pathway results in overactivation of glutamatergic projections to the striatum and basal ganglia output nuclei. In addition, NMDARs have been proposed to play a role in the development of levodopainduced dyskinesias. Accordingly, the therapeutic potential of NMDAR antagonists has been investigated, and broadspectrum antagonists have been shown to exhibit antiparkinsonian or antidyskinetic activity in rodent and monkey models, and the low affinity NMDAR antagonist amantadine has been shown to exhibit antidyskinetic activity in humans (Del Dotto et al., 2001) . Subsequently, NR2B-selective antagonists have been shown to exhibit efficacy in preclinical models of Parkinsonism in both rodents and non-human primates (e.g. Steece-Collier et al., 2000; Loschmann et al., 2004; Wessell et al., 2004) , with an apparently improved tolerability profile relative to broad-spectrum antagonists. While ifenprodil failed to show a significant benefit in a small clinical trial in Parkinson's disease patients as adjunct therapy to L-DOPA (Montastruc et al., 1992) , in a recent study, CP-101,606 exhibited antidyskinetic but not antiparkinsoAllosteric modulators of NR2B-containing NMDA receptors L Mony et al nian effects, although at doses associated with dissociation and amnesia (Nutt et al., 2008) . Further studies are required to determine whether therapeutic efficacy can be achieved at lower doses, in the absence of adverse cognitive effects. A phase 1 study with MK-0657 as adjunct therapy to levodopa has also been reported as completed, although data have not yet been disclosed (Table 1) .
Huntington's disease
Huntington's disease is an autosomal dominant inherited disease characterized by selective neuronal degeneration, most prominently of striatal GABAergic medium-sized spiny neurons. The disorder results from expression of mutant forms of the huntingtin gene, which contain an expanded trinucleotide CAG repeat sequence encoding an extended polyglutamate tract in the translated protein. Studies of animal and cellular models expressing mutant forms of the huntingtin protein have implicated NMDAR dysregulation and subsequent excitotoxic damage in the pathophysiology of the disease. For example, in a mouse model of Huntington's disease, striatal GABAergic medium-sized neurons show a selective enhancement of NMDAR currents mediated by NR2B-containing receptors (Zeron et al., 2002) and this increase may underlie the selective neuronal loss in Huntington's disease (Li et al., 2003) . Thus, early intervention with selective NR2B antagonists at the onset of pathology, or presymptomatically, may offer therapeutic potential in this disorder.
Alzheimer's disease
The low affinity, broad-spectrum NMDAR channel blocker memantine has been approved in both the USA and Europe for the treatment of moderate to severe Alzheimer's disease. As NMDAR activity is well recognized to play a critical role in learning and memory, the efficacy of memantine as a symptomatic, cognitive-enhancing therapy in Alzheimer's disease appears, at first sight, to be counter-intuitive. Memantine is a low-affinity, voltage-dependent uncompetitive antagonist with fast dissociation kinetics, and it has been proposed that it mediates efficacy through normalizing aberrant, diseaseassociated low level NMDAR activation without impairing physiological synaptic receptor activation, in a manner somewhat analogous to the endogenous NMDAR channel blocker, magnesium (Parsons et al., 2007) . As such, it is thought to improve the 'signal to noise' characteristics of NMDAR signalling in the diseased brain. NR2B-containing NMDARs, which are enriched in the extrasynaptic receptor population, represent plausible candidates for mediating such disease-associated 'background' NMDAR activation. Preclinical studies in healthy adult rats that notably do not exhibit the proposed disease-associated NMDAR dysfunction provide some support for the rationale of selectively targeting NR2B-containing receptors in terms of absence of cognitive impairment and evidence for cognitive enhancement. Thus, CP-101,606 at a dose which fully occupied hippocampal NR2B-containing receptors did not impair spatial learning or memory in the Morris water maze task in healthly adult rats (in contrast to the broad-spectrum channel blocker MK-801; Guscott et al., 2003) . In addition, while CP-101,606 promoted impulsive-type responding, it improved task performance in a rat delayed match to position task (Higgins et al., 2005) . Thus, NR2B-selective antagonists may have therapeutic potential as cognitive enhancers in Alzheimer's disease, and Evotec is currently developing EVT-101 for this indication (Table 1) .
Cerebral ischaemia and traumatic brain injury
The role of CNS glutamate receptors and, particularly, the highly calcium permeable NMDARs in mediating the excitotoxic neuronal cell damage observed in both cerebral ischaemia and traumatic brain injury is well recognized. Accordingly, broad-spectrum NMDAR antagonists have been shown to be neuroprotective when administered before or shortly after traumatic brain injury or ischaemic insult in animal models (Kemp et al., 1999) . However, the promise of preclinical data has not been realized in patients with several agents, failing to show efficacy in clinical studies (e.g. Morris et al., 1999; Lees et al., 2000; Albers et al., 2001) . It has been speculated that the dose-limiting side effects associated with such broad-spectrum NMDAR antagonists may have contributed to the failure of these studies. NR2B-selective antagonists may offer potential as efficacious neuroprotective agents with an acceptable tolerability profile. In support, data from several studies suggest that activation of extrasynaptic (mostly NR2B-containing) receptors triggers pro-death signalling events, while activation of synaptic (mostly NR2A-containing) receptors favours neuronal survival (Hardingham and Bading, 2003; Zhou and Baudry, 2006; von Engelhardt et al., 2007; Liu et al., 2007; Chen et al., 2008; Martel et al., 2009) . However, while NR2B-selective antagonists are neuroprotective in animal models with an improved therapeutic index relative to broad-spectrum antagonists (Kemp et al., 1999; Tahirovic et al., 2008) , clinical studies have yielded disappointing outcomes, with CP-101,606 failing to demonstrate efficacy, despite an apparently acceptable tolerability profile (Merchant et al., 1999; Saltarelli et al., 2004) .
Major depression
Following the demonstration of antidepressant-like activity of broad-spectrum NMDAR antagonists in animal models, two small crossover clinical studies have reported a positive antidepressant effect of the NMDAR channel blocker ketamine (Berman et al., 2000; Zarate et al., 2006) . Notably, the antidepressant effect exhibited a rapid onset and persisted for several days after single dose administration (Zarate et al., 2006) , presenting a potentially attractive therapeutic profile. However, the clinical applicability of ketamine is limited by its psychomimetic activity, which was observed in both studies. Preclinically, NR2B-selective antagonists have also been reported to exhibit antidepressant activity (Maeng and Zarate, 2007) , and recently a randomized, double-blind study in patients with refractory major depressive disorder treated with CP-101,606 was reported (Preskorn et al., 2008) . In this parallel group study, subjects with major depression and a history of treatment refractoriness to selective serotonin reuptake inhibitors (SSRI) first received 6 weeks open-label treatment with the SSRI paroxetine followed by a single-blind placebo infusion. Paroxetine non-responders (n = 30) were then randomized to a single infusion of CP-101,606 or placebo plus continued treatment with paroxetine for up to a further 4 weeks. CP-101,606 was generally well tolerated and its administration produced a greater antidepressant effect than placebo, thus, illustrating antidepressant potential for NR2B subtype-selective antagonists in otherwise treatment refractory patients. A further clinical study in refractory depression has recently been initiated with MK-0657 (Table 1) .
Positive modulation of NR2B-containing NMDA receptors
As discussed above, a number of NMDAR positive modulators have been identified, including polyamines, neurosteroids and Mg 2+ , some of which exhibit subunit selectivity. Based on the increasing understanding of receptor structure and the molecular mechanisms underlying both positive modulation by such ligands and subunit-selective antagonism, it seems reasonable to expect that appropriately configured screening campaigns might identify novel, subunit-selective small molecule positive modulators. Subunit-selective positive modulation might represent a strategy to enhance receptor function, for example, under pathological conditions of receptor hypofunction, without triggering excitotoxicity through receptor overactivation. NMDAR hypofunction has been implicated in the pathophysiology of schizophrenia, initially based on the psychomimetic activity of the broad-spectrum ion channel blockers, ketamine and PCP, which have been reported to elicit a schizophrenia-like phenotype in healthy volunteers, encompassing the characteristic positive, negative and cognitive symptoms of the disease (see, e.g. Krystal et al., 2005) . Subsequent neurophysiological, neuroanatomical and biochemical studies have provided support for disease-associated NMDAR hypofunction (e.g. Umbricht and Krljes, 2005; Hahn et al., 2006; Woo et al., 2008) . Efforts to enhance diseaseassociated receptor hypofunction to date have centred on strategies to enhance glycine site occupancy and, hence, receptor tone, either through the administration of agonists (glycine, D-serine) or via inhibition of the GLYT1 glycine transporter, and these studies have yielded encouraging preliminary data (Javitt, 2008) . The preferred target NMDAR subunit for a novel small molecule positive modulator approach is unclear. In support of NR2B, its transgenic overexpression resulted in mice with improved learning and memory (Tang et al., 1999) , and gene knockout/knockdown resulted in learning and memory impairments (von Engelhardt et al., 2008) . Thus, selective positive modulation of NR2B-containing NMDARs might represent a novel therapeutic strategy for the treatment of schizophrenia and, potentially, other cognitive disorders.
Conclusion
By combining biochemical, structural and functional studies, much progress has been made in recent years in the comprehension of the mechanisms by which extracellular agents can affect NMDAR activity. In particular, it has become increasingly clear that the large NTD of NR2 subunits, which precedes the glutamate-binding domain, is a major site for subunit-specific allosteric modulation. In that respect, receptors incorporating the NR2B subunit appear particularly interesting because the NR2B-NTD not only harbours sites for negative allosteric modulators (such as zinc and ifenprodil) but might also confer a unique sensitivity to the positive allosteric modulators polyamines and Mg 2+ by participating in an inter-subunit regulatory site. Finally, our increasing understanding of NMDAR structure, function and pharmacology is now translating into promising therapeutic strategies to target NMDAR dysregulation. The therapeutic utility of broadspectrum NMDAR antagonists is typically limited by their associated side effects. Newer, subtype-selective negative modulators of receptor function, primarily targeting NR2B-containing receptors, have entered clinical development and offer improved potential for the treatment of patients suffering from a range of debilitating psychiatric and neurological disorders. Opportunities for selective positive modulation of NMDARs and to selectively target other NMDAR subtypes or their downstream regulatory cascades are currently more limited but are likely to be a focus of future research. The advent of biological therapeutic agents, such as antibodies (or fragments thereof), and RNA inhibition may also enable therapeutic interventions considered intractable using existing small molecule approaches.
Conflicts of interest
LM and PP declare no conflict of interest. MJG and JK are employees of GlaxoSmithKline PLC.
